[AMGN] Amgen Inc.


Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 147.55 Change: 1.19 (0.81%)
Ext. hours: Change: 0 (0%)

chart AMGN

Refresh chart

Strongest Trends Summary For AMGN

AMGN is in the long-term up 290% in 14 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company?s principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS10.63 EPS Growth - 4 Quarters-5.54% EPS Growth - Q/Q23.37%
EPS Growth - Y/Y-9.79% Sales Growth - 4 Quarters -2.84% Sales Growth - Q/Q-5.59% P/E15.28
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA8.28% ROE21.53% ROI9.63%
Current Ratio5.53 Quick Ratio5.11 Long Term Debt/Equity1.04 Debt Ratio0.24
Gross Margin78.78% Operating Margin33.29% Net Profit Margin27.74% Dividend Payout Ratio-34.86%
Dividend Yield
Fundamental Data
Cash From Financing Activities-1.24 B Cash From Investing Activities-952 M Cash From Operating Activities1.33 B Gross Profit4.57 B
Net Profit1.65 B Operating Profit2.08 B Total Assets71.21 B Total Current Assets37.74 B
Total Current Liabilities6.89 B Total Debt31.95 B Total Liabilities43.73 B Total Revenue5.37 B
Technical Data
High 52 week206.65 Low 52 week164.03 Last close189.81 Last change1.23%
RSI59.81 Average true range3.52 Beta0.85 Volume2.05 M
Simple moving average 20 days1.65% Simple moving average 50 days-0.4% Simple moving average 200 days-0.55%
Performance Data
Performance Week0.78% Performance Month-4.82% Performance Quart-2.62% Performance Half-3.4%
Performance Year4.82% Performance Year-to-date-1.74% Volatility daily1.57% Volatility weekly3.5%
Volatility monthly7.18% Volatility yearly24.88% Relative Volume183.77% Average Volume3.21 M
New High New Low


2019-04-21 09:00:00 | Amgen: This Beaten Down Blue Chip Is Priced To Own

2019-04-18 23:12:03 | The Top 10 Biotechnology Companies JNJ, ROG.VX

2019-04-18 10:59:02 | Can Q1 Earnings Lift Healthcare ETFs Higher?

2019-04-18 07:26:08 | 3 Big Stock Charts for Thursday: Citrix Systems, Goldman Sachs Group and Amgen

2019-04-17 16:00:00 | Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida

2019-04-17 10:06:04 | Amgen Falls 3%

2019-04-16 18:54:10 | Radius Health RDUS Rallies 33.4% YTD on Robust Tymlos Sales

2019-04-16 10:52:33 | Why Amgen Stock Could Break Out to New Highs

2019-04-15 16:03:30 | Amgen sets $21,900 annual price for new Evenity bone drug

2019-04-15 16:00:00 | EVENITY™ romosozumab-aqqg Now Available In The United States For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

2019-04-15 09:56:01 | The Zacks Analyst Blog Highlights: Bank of America, Amgen, NextEra, T-Mobile and S&P Global

2019-04-15 06:58:11 | Goldman Sachs's 20 best stocks to invest in now

2019-04-13 12:28:00 | Better Buy: Amgen vs. Gilead Sciences

2019-04-13 09:38:23 | The Week Ahead In Biotech: Conferences, Clinical Trial Readouts, Earnings And IPOs

2019-04-12 13:45:05 | Top Analyst Reports for Bank of America, Amgen & NextEra Energy

2019-04-12 11:08:03 | Merck's Keytruda Gets FDA Nod for Expanded Lung Cancer Group

2019-04-12 07:06:03 | 8 Stocks May Jump on Takeovers as Market Nears Peak

2019-04-11 05:31:47 | 8 Stocks to Own in 2Q as the Market Enters Rough Waters

2019-04-10 10:30:02 | Akebia Expands Vadadustat Licensing Deal With Vifor Pharma

2019-04-10 10:16:02 | Amgen's AMGN Osteoporosis Drug Evenity Gets FDA Approval

2019-04-10 09:44:26 | Second Time's The Charm For Amgen As FDA OKs Bone-Building Osteoporosis Drug

2019-04-10 09:20:01 | Biotech Stock Roundup: AMGN's Evenity Earns FDA Approval, Deal Wins & More

2019-04-10 07:32:46 | The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering

2019-04-09 17:16:44 | Amgen's postmenopausal osteoporosis drug gets FDA greenlight

2019-04-09 16:09:00 | FDA approves Amgen's Evenity for treatment of osteoporosis in postmenopausal women

2019-04-09 15:57:00 | FDA Approves EVENITY™ romosozumab-aqqg For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture

2019-04-09 13:23:00 | Here's Why Novartis Is Sliding Today

2019-04-09 10:52:00 | Why bluebird bio Could Deliver Miracles to Genetic Disease Patients

2019-04-09 10:44:07 | See what the IHS Markit Score report has to say about Amgen Inc.

2019-04-09 10:23:00 | Why Amgen Can Deliver Medical and Financial Miracles

2019-04-09 09:53:00 | 5 Stocks in the Age of Miracles

2019-04-07 18:31:00 | Why Amgen's Giving Novartis a Headache

2019-04-07 05:00:00 | Amgen Presents New Data At WCO-IOF-ESCEO 2019 Revealing Osteoporosis Treatment Gap In Europe

2019-04-05 14:00:00 | Lawsuit over migraine deal could be good for Amgen, analysts say

2019-04-05 10:14:02 | Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig

2019-04-05 10:10:02 | Why Amgen AMGN is Poised to Beat Earnings Estimates Again

2019-04-05 07:48:37 | The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership

2019-04-04 17:16:55 | Novartis, Amgen in dispute over migraine drug partnership

2019-04-04 16:29:38 | Novartis Lawsuit Accuses Amgen Of Trying To Welsh On Migraine Deal

2019-04-04 10:26:02 | Pfizer's New Lung Cancer Drug Vizimpro Gets EU Approval

2019-04-04 09:39:01 | Novartis Resubmits BLA to FDA for Biosimilar of Neulasta

2019-04-03 00:00:42 | Oxford Nanopore’s listing plan a boost for Neil Woodford

2019-04-03 00:00:42 | Oxford Nanopore’s flotation plans are a boon for Neil Woodford

2019-04-02 09:36:01 | Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe

2019-04-01 07:06:04 | Does Amgen Inc.'s NASDAQ:AMGN P/E Ratio Signal A Buying Opportunity?

2019-04-01 07:02:21 | BMO’s Got A Point About Teva Stock, But Are Investors Willing To Listen?

2019-03-30 12:00:00 | 3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop

2019-03-29 10:36:02 | 4 Small Biotech Stocks Likely to Witness More Upside in 2019

2019-03-28 17:44:58 | AbbVie's big acquisition blowup: A one-off or an omen?

2019-03-28 15:08:18 | Analysts Raise Their Target Price for Amgen in March